CINECA IRIS Institutional Research Information System
IRIS è la soluzione IT che facilita la raccolta e la gestione dei dati relativi alle attività e ai prodotti della ricerca. Fornisce a ricercatori, amministratori e valutatori gli strumenti per monitorare i risultati della ricerca, aumentarne la visibilità e allocare in modo efficace le risorse disponibili.
EnglishWhen treating HCV patients with conventional dual therapy in the current context of rapidly evolving HCV therapy, outcome prediction is crucial and HCV kinetics, as early as 48 hours after the start of treatment, may play a major role. We aimed at clarifying the role of HCV very early kinetics. We consecutively enrolled mono-infected HCV patients at 7 treatment sites in Central Italy and evaluated the predictive value of logarithmic decay of HCV RNA 48 hours after the start of dual therapy (Delta48). Among the 171 enrolled patients, 144 were evaluable for early and sustained virological response (EVR, SVR) prediction; 108 (75.0%) reached EVR and 84 (58.3%) reached SVR. Mean Delta48 was 1.68±1.22 log10 IU/ml, being higher in patients with SVR and EVR. Those genotype-1 patients experiencing a Delta48 >2 logs showed a very high chance of success (100% positive predictive value), even in the absence of rapid virological response (RVR). Evaluation of very early HCV kinetics helped identify a small but significant proportion of genotype-1 patients (close to 10%) in addition to those identified with RVR, who could be treated with dual therapy in spite of not reaching RVR. In the current European context, whereby sustainability of HCV therapy is a crucial issue, conventional dual therapy may still play a reasonable role in patients with good tolerance and early prediction of success.
Tontodonati, M., Cento, V., Polilli, E., Colabattista, C., Cascella, R., Sciotti, M., et al. (2015). May some HCV genotype 1 patients still benefit from dual therapy? The role of very early HCV kinetics. NEW MICROBIOLOGICA, 38(4), 491-497.
| Tipologia: | Articolo su rivista |
| Citazione: | Tontodonati, M., Cento, V., Polilli, E., Colabattista, C., Cascella, R., Sciotti, M., et al. (2015). May some HCV genotype 1 patients still benefit from dual therapy? The role of very early HCV kinetics. NEW MICROBIOLOGICA, 38(4), 491-497. |
| IF: | Con Impact Factor ISI |
| Lingua: | English |
| Settore Scientifico Disciplinare: | Settore MED/07 - Microbiologia e Microbiologia Clinica |
| Revisione (peer review): | Sì, ma tipo non specificato |
| Tipo: | Articolo |
| Rilevanza: | Rilevanza internazionale |
| Stato di pubblicazione: | Pubblicato |
| Data di pubblicazione: | nov-2015 |
| Titolo: | May some HCV genotype 1 patients still benefit from dual therapy? The role of very early HCV kinetics |
| Autori: | |
| Autori: | Tontodonati, M; Cento, V; Polilli, E; Colabattista, C; Cascella, R; Sciotti, M; Di Giammartino, D; Trave, F; Di Maio, VC; Monarca, R; Di Candilo, F; Prinapori, R; Rastrelli, E; Vecchiet, J; Ceccherini Silberstein, F; Manzoli, L; Giardina, E; Perno, CF; Parruti, G |
| Appare nelle tipologie: | 01 - Articolo su rivista |
File in questo prodotto:
| File | Descrizione | Tipologia | Licenza | |
|---|---|---|---|---|
| 2015_May some HCV genotype 1 patients still benefit from dual therapy The role of very early HCV kinetics_Tontodonati_NewMicrobiologica.pdf | N/A | Copyright dell'editore | Open Access Visualizza/Apri |
Copyright © 2020